Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

Schizophrenia drug didn't do well in the lab Just before the market open on Monday, AbbVie revealed that its emraclidine ...

And Cerevel Therapeutics, which had positive early testing results for emraclidine, its drug that aims to treat schizophrenia ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...